doi: 10.1016/j.bmcl.2004.04.065.
Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines
Affiliations
- PMID: 15177480
- DOI: 10.1016/j.bmcl.2004.04.065
Item in Clipboard
Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines
Bioorg Med Chem Lett.
.
Abstract
A novel series of 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines was synthesized and their TbetaR-1 inhibitory, p38 MAPK inhibitory, and TbetaR-1-dependent cellular activity were evaluated. Compound 5a was found to be a highly potent in the enzyme assay and TbetaR-1-dependent cellular assays. In addition, dimer (4g), with a urea linker, shows a similar enzyme and cellular activity despite a bulky substitution.
Similar articles
-
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.Bioorg Med Chem Lett. 2004 Jul 5;14(13):3581-4. doi: 10.1016/j.bmcl.2004.04.007. Bioorg Med Chem Lett. 2004. PMID: 15177479
-
Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.J Med Chem. 2006 Apr 6;49(7):2210-21. doi: 10.1021/jm0509905. J Med Chem. 2006. PMID: 16570917
-
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.J Med Chem. 2004 Aug 26;47(18):4494-506. doi: 10.1021/jm0400247. J Med Chem. 2004. PMID: 15317461
-
Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.J Med Chem. 2003 Sep 11;46(19):3953-6. doi: 10.1021/jm0205705. J Med Chem. 2003. PMID: 12954047
-
Inhibition of ALK5 as a new approach to treat liver fibrotic diseases.Drug News Perspect. 2006 Mar;19(2):85-90. doi: 10.1358/dnp.2006.19.2.977444. Drug News Perspect. 2006. PMID: 16628263 Review.
Cited by
-
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.Drug Des Devel Ther. 2015 Aug 10;9:4479-99. doi: 10.2147/DDDT.S86621. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26309397 Free PMC article. Review.
-
Small molecule antagonists of the TGF-beta1/TGF-beta receptor binding interaction.Med Oncol. 2006;23(4):553-62. doi: 10.1385/MO:23:4:553. Med Oncol. 2006. PMID: 17303915
-
Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.Oncol Lett. 2015 Jun;9(6):2442-2448. doi: 10.3892/ol.2015.3106. Epub 2015 Apr 8. Oncol Lett. 2015. PMID: 26137087 Free PMC article.
-
Peptide ligands that use a novel binding site to target both TGF-β receptors.Mol Biosyst. 2010 Dec;6(12):2392-402. doi: 10.1039/c0mb00115e. Epub 2010 Oct 4. Mol Biosyst. 2010. PMID: 20890540 Free PMC article.
-
Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.Cell Oncol (Dordr). 2015 Apr;38(2):131-44. doi: 10.1007/s13402-014-0210-8. Epub 2015 Jan 9. Cell Oncol (Dordr). 2015. PMID: 25573078 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information
